Research from the American Diabetes Association , shows promise that aspirin may be beneficial for diabetics. Investigators have found evidence in vivo (living bodies) of excess thromboxane release in patients with type 2 diabetic who also have cardiovascular disease.
Thromboxane causes blood to clot and blood vessels to constrict. Aspirin prevents this from happening, and has been used as both a primary and secondary measure to prevent cardiovascular events in diabetics as well as non diabetics.
Meta-analyses of these studies, along with large-scale collaborative trials in male and female diabetics, support the viewpoint, that low-dose aspirin therapy should be prescribed as a secondary diabetes prevention strategy, if no contraindications exist.
There is also substantial evidence which indicates that low-dose aspirin therapy should be considered as a primary prevention strategy in men and women over age 40, who have been diagnosed with diabetes who are also at high risk, for cardiovascular events.
Additional research was done on 145 individuals, who had previously been diagnosed with cardiovascular events such as angina, heart attack, stroke, or angioplasty. The results indicate a one quarter reduction in each of these categories. It was also noted that a daily dose of 75-162 mg of aspirin led to a larger decrease in vascular issues.
It is unfortunate, that in spite of Aspirins proven track record, less than half of diabetics are being treated with aspirin therapy. Do not use aspirin as a replacement for any medication that has been prescribed for you. Please check with your health care provider to see if aspirin therapy may be beneficial for you.